Profusa Expands into Precision Diagnostics with $30M PanOmics Platform Acquisition and Mayo Clinic Partnership
核心洞察
Profusa (搜索) announced a Letter of Intent to acquire the PanOmics (搜索) multi-omics diagnostics platform from BioInsights LLC (搜索) for $30 million in equity securities, expanding beyond its core biosensing technology.
The acquisition includes exclusive access to clinically annotated samples and established assay infrastructure, creating an accelerated pathway to lab developed test commercialization.
The company is integrating the platform with its Lumee (搜索) oxygen monitoring technology through a Mayo Clinic partnership to address pancreatic cancer (搜索) surgical monitoring challenges.
Profusa (搜索), Inc. (Nasdaq: PFSA), a commercial-stage digital health company specializing in continuous biochemistry monitoring, announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics (搜索) multi-omics diagnostics platform from BioInsights LLC (搜索) for approximately $30 million. The acquisition positions the Berkeley-based company at the intersection of biosensing, diagnostics, and precision medicine while establishing a foundation for a scalable multi-product diagnostics franchise.
"This is a pivotal step in the evolution of Profusa (搜索)," said Dr. Ben Hwang, Profusa Chairman and Chief Executive Officer. "The combination of the PanOmics (搜索) platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring."
Strategic Transaction Details
Under the terms of the Letter of Intent, Profusa (搜索) would acquire exclusive rights to the PanOmics (搜索) platform and related intellectual property for total consideration of approximately $30 million, to be paid in equity securities. The transaction includes several key provisions:
- BioInsights will provide access to a specified number of samples for validation purposes
- BioInsights will receive a 3% royalty on net revenue from the platform
- BioInsights gains the right to nominate one independent Board member for stockholder consideration
- Profusa intends to pursue additional financing to support development and scaling efforts
The proposed transaction remains subject to completion of due diligence, shareholder approval, and customary closing conditions.
Accelerated Commercialization Pathway
The BioInsights acquisition provides Profusa (搜索) with exclusive access to clinically annotated samples for validation and established assay design infrastructure, creating what the company believes is a defined pathway to rapidly validated lab developed test (LDT) commercialization. These assets are expected to enable a capital-efficient and accelerated path from development to revenue generation.
The integration of the PanOmics (搜索) platform with Profusa (搜索)'s existing biosensing technologies creates opportunities to develop multi-indication diagnostic assays, real-time physiological monitoring solutions, and data-driven clinical decision tools. The company believes this combined approach can support expansion into multiple high-growth markets and establish a scalable, recurring-revenue diagnostics and monitoring platform.
Pancreatic Cancer Focus and Mayo Clinic Partnership
The platform will be integrated into Profusa (搜索)'s emerging vertical addressing pancreatic cancer (搜索) challenges. The company is collaborating with Mayo Clinic to leverage its Lumee (搜索) oxygen platform for critical intraoperative and postoperative monitoring in complex pancreatic procedures.
Pancreatic cancer (搜索) represents one of the most challenging surgical oncology areas, with more than 13,000 resections performed annually in the United States, representing an estimated $26 million annual revenue opportunity. Dr. Hwang emphasized that "the entry into pancreatic cancer is instrumental in our establishing a platform capable of supporting multiple indications and long-term growth."
Technology Platform Integration
Profusa (搜索)'s core technology involves tissue-integrated sensors that detect and continuously transmit medical-grade data for personal and clinical use. The company's long-lasting, injectable biosensors combined with its intelligent data platform aim to provide personalized biochemical signatures that clinicians can trust and rely upon.
The addition of the PanOmics (搜索) multi-omics diagnostics platform expands Profusa (搜索)'s capabilities beyond real-time monitoring into comprehensive molecular diagnostics, potentially creating synergies between continuous monitoring and diagnostic testing applications.
Financial Impact and Future Development
The transaction is expected to add $30 million of shareholder equity to Profusa (搜索)'s balance sheet while providing access to established diagnostic infrastructure and clinical samples. With access to clinical samples, a clear validation pathway, and the Mayo Clinic collaboration, Profusa believes it is positioned to accelerate development, drive clinical adoption, and unlock near-term commercial value in the precision diagnostics market.